



FINANCIAL TEAR SHEET

CORPORATE PROFILE


Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$11.10
Change (%)	▼ 0.25 (2.20%)
Volume	400,848
52 Week Low	\$10.80
Market Cap	\$569,948,226
Rolling EPS	-2.25
PE Ratio	N/A
Shares Outstanding	51,346,687

Data as of 08/18/17 4:00 p.m. ET



RECENT NEWS & UPCOMING EVENTS

08/07/17

[Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results](#)

08/07/17

[Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522](#)

07/24/17

[Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
08/11/17	<u>8-K</u>
08/10/17	<u>4</u>
08/10/17	<u>SC 13G</u>
08/08/17	<u>4</u>

CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.